Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 15

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 3
Chunk 15
---
 the company’s growth and performance. Competition for highly skilled personnel
and agents is often intense and NewGenIvf may incur significant costs or may not be successful in attracting, integrating, or retaining
qualified personnel and agents to fulfill NewGenIvf’s current or future needs. NewGenIvf believes that the granting of share-based
awards is of significant importance to NewGenIvf’s ability to attract and retain agents, key personnel and employees, and NewGenIvf
will continue to grant share-based awards in the future. In addition, NewGenIvf may, with the approval of its Compensation Committee and
the Board, revise the terms of, and increase the size of, its share incentive plan, to ensure that it is able to attract and retain agents,
key personnel and employees. On March 31, 2025, NewGenIvf’s Board approved certain amendments to its Share Incentive Plan, including
the increase of the size of the share incentive plan to 20% of the outstanding shares of the Company from time to time. As a result, NewGenIvf’s
expenses associated with share-based compensation may increase, which may have an adverse effect on NewGenIvf’s results of operations.
The amended share incentive plan is available as Exhibit 4.21.

To successfully market and sell its services
and products in Asia-Pacific markets, NewGenIvf must address many international business risks with which NewGenIvf has limited experience.

NewGenIvf’s business
is subject to risks in connection with changes in international, national and local economic and market conditions, including the effects
of global financial crises, effects of terrorist acts and war and global pandemics. Such economic changes could negatively impact infertile
couples’ abilities to pay for fertility treatments around the world.

NewGenIvf’s strategy
is to increase its international presence in Asia-Pacific countries and its international sales are subject to a number of risks, including:

  increased competition as a result of more products and procedures receiving regulatory approval or otherwise free to market in international markets;  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  longer accounts receivable payment cycles and difficulties in collecting accounts receivable;  

  reduced or varied protection for intellectual property rights in some countries;  

  export restrictions, trade regulations, and foreign tax laws;  

  fluctuations in currency exchange rates;  
 ────────────────────────────────────────────

  foreign certification and